10.1097/00001756-200401190-00002 Neuroreport 93 KatoT.FunakoshiH.KadoyamaK.NomaS.KanaiM.Ohya-ShimadaW.et al (2012)
Enebo L.B., Berthelsen K.K., Kankam M., et al
There is a well-recognized phenomenon in gut-hormone pharmacology whereby a signal that potently slows gastric emptying on first exposure gradually loses that particular effect under continuous stimulation, even as its central appetite-suppressing effect persists
In 1990, the US Congress passed an omnibus crime bill, the Crime Control Act of 1990, that amended the Federal Food, Drug, and Cosmetic Act, that classified anabolic steroids as controlled substances and added a new section that stated that a person who "knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary of Health and Human Services" has committed a felony
But you just got to have that boss in your brain has to be in control
Satiety and Food Intake Reduction Cagrilintide's most clinically significant effect is its potent reduction in food intake and enhancement of satiety through activation of AMY1 receptors in the area postrema [14] : Brainstem Satiety Signaling: Area postrema neurons project to nucleus tractus solitarius (NTS), which integrates peripheral satiety signals and regulates feeding behavior [17] Dose-Dependent Effects: Higher doses of cagrilintide produce greater reductions in ad libitum food intake and increased subjective fullness ratings [9] Sustained Effect: Unlike acute satiety signals, cagrilintide's long half-life provides continuous appetite suppression between weekly doses [2] Synergy with GLP-1 Receptor Agonists The combination of cagrilintide with GLP-1 receptor agonists (particularly semaglutide) produces effects greater than either agent alone
